pioglitazone has been researched along with Atherosclerotic Parkinsonism in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bonato, JM | 1 |
Bassani, TB | 1 |
Milani, H | 1 |
Vital, MABF | 1 |
de Oliveira, RMW | 1 |
Ulusoy, GK | 1 |
Celik, T | 1 |
Kayir, H | 1 |
Gürsoy, M | 1 |
Isik, AT | 1 |
Uzbay, TI | 1 |
2 other studies available for pioglitazone and Atherosclerotic Parkinsonism
Article | Year |
---|---|
Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; Hippocampus; Male; Mortality; Ne | 2018 |
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Mot | 2011 |